spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Neovasc 

 HSMN NewsFeed - 3 Jul 2023
Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
Regenerative Medicine Ophthalmology FDA
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 29 Jun 2022
EYLEA(R) (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2022
Acera Surgical Announces Michael Finegan as New CEO
Devices Surgery Wound Care Personnel
 HSMN NewsFeed - 13 Sep 2021
AbbVie and REGENXBIO Announce Eye Care Collaboration
Biopharmaceuticals Regenerative Medicine Ophthalmology
 HSMN NewsFeed - 7 Apr 2021
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
Devices Ophthalmology
 HSMN NewsFeed - 18 Feb 2020
LumiThera to Expand Research into Diabetic Retinopathy for Valeda(R) Light Delivery System
Devices Ophthalmology
 HSMN NewsFeed - 13 Jan 2020
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 12 Jul 2019
Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2019
Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara(TM)
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 14 Mar 2019
Clinical Study Demonstrates Long Term IOP Reduction with the OMNI(R) Surgical System Predicate Device (TRAB(R)360) in Micro-Invasive Glaucoma Surgery
Devices Ophthalmology
 HSMN NewsFeed - 20 Feb 2019
Neovasc Provides Corporate Update
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 20 Feb 2019
ROKIT Healthcare Announces a Novel Application of Dermal Regeneration Platform Using Proprietary Three-Dimensional Bioprinting Strategy
Regenerative Medicine
 HSMN NewsFeed - 11 Feb 2019
Pierangeli Clinic Initiates Program Providing Neovasc Reducer(TM) Procedure to Italian Patients with Refractory Angina
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Jan 2019
Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 11 Dec 2018
Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer(TM) as Published in JACC
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Oct 2018
Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer(TM)
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2018
Neovasc Announces First Implant of a Neovasc Reducer(TM) in a U.S. Patient
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jun 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
Devices Cardiology Personnel
 HSMN NewsFeed - 25 May 2018
Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Apr 2018
ACell, Inc. Announces Launch of Gentrix(R) Incisional
Devices Surgery Product Launch
 HSMN NewsFeed - 19 Mar 2018
EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Feb 2018
Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer(TM) Procedure for Treatment of Refractory Angina
Devices Interventional Cardiology Reimbursement
 HSMN NewsFeed - 22 Jan 2018
Fred Colen Appointed Chief Executive Officer of Neovasc Inc.
Devices Interventional Cardiology Personnel
 HSMN NewsFeed - 9 Nov 2017
Johnson & Johnson Vision Announces Series of Product Milestones and Launches Across Portfolio at American Academy of Ophthalmology 2017 Meeting
Devices Ophthalmology Product Launch
 HSMN NewsFeed - 6 Nov 2017
Neovasc Receives FDA Approval to Initiate Pivotal Reducer Trial
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 12 Sep 2017
Neovasc Provides Tiara(TM) Clinical Update
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Sep 2017
Neovasc's Reducer System Reviewed in European Heart Journal
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Aug 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Jun 2017
Ocugen Makes Strategic Appointments to Management Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 30 Mar 2017
Boston Scientific Announces Agreement to Acquire Symetis
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Dec 2016
Boston Scientific Closes Acquisition of Advanced Biological Tissue Capabilities and Acquires Common Shares of Neovasc, Inc.
Devices Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 12 Dec 2016
Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent(R) Trabecular Micro-Bypass Stent as a Standalone Procedure
Devices Ophthalmology
 HSMN NewsFeed - 6 Dec 2016
Neovasc Provides Update on its Tiara(TM) Mitral Valve Clinical Program
Devices Cardiology Surgery
 HSMN NewsFeed - 2 Dec 2016
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
Devices Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 22 Nov 2016
Allergan Receives FDA Clearance for the XEN(R) Gel Stent, a New Surgical Treatment for Refractory Glaucoma
Devices Ophthalmology FDA
 HSMN NewsFeed - 11 Nov 2016
Sofregen Medical Acquires SERI(R) Surgical Scaffold Product Line from Allergan
Devices Surgery Acquisitions
 HSMN NewsFeed - 1 Nov 2016
Neovasc Announces Update in Litigation with CardiAQ
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 11 Oct 2016
FDA Grants Priority Review to Genentech’s Lucentis(R) (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 4 May 2016
Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer
Devices Monitoring Ophthalmology Personnel
 HSMN NewsFeed - 30 Oct 2015
Regeneron Announces EU Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 21 Oct 2015
Allegro Ophthalmics Names Scott Cooper as Chief Financial Officer and Vice President of Business Development and Mohamed Genead, MD, as Executive Medical Director
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Jul 2015
Ophthotech Announces New Senior Leadership Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 26 Feb 2015
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 9 Oct 2014
Neovasc Receives FDA Conditional Approval to Initiate TIARA-I Trial in US: A Multinational, Multicenter Early Feasibility Trial of the Tiara(TM) Transcatheter Mitral Valve
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 22 Sep 2014
Regeneron Announces EYLEA(R) (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 8 May 2014
Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs
Devices Cardiology Personnel
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Feb 2014
Neovasc Inc. Announces Successful First Human Implant of Tiara(TM) Transcatheter Mitral Valve
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Jan 2014
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
Diagnostics Ophthalmology Licensing
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 15 Nov 2013
Lumenis Receives US FDA and Japanese MHLW Clearance for Array(TM) LaserLink(TM) Pattern Scanning Device for Multi-Spot Retinal Laser Treatment
Devices Ophthalmology FDA Regulatory
 HSMN NewsFeed - 12 Nov 2013
Bayer receives approval for Eylea(R) as new drug to treat wet Age-Related Macular Degeneration Patients in Canada
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 6 Nov 2013
Neovasc Reducer(TM) Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Functional Capabilities in Patients with Refractory Angina
Devices Cardiology
 HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 May 2013
Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer(TM) Improves Cardiovascular Parameters in Refractory Angina Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Mar 2013
RTI Biologics(R) Receives 510(k) Clearance for Porcine Dermis Implant
Devices Surgery FDA
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 1 Nov 2012
Neovasc Inc. Finalizes US $4.6 Million Agreement Giving Lemaitre Vascular Rights to In-House Manufacture of Xenosure(R) Surgical Patch
Devices Surgery Licensing
 HSMN NewsFeed - 30 Aug 2012
Aerpio Therapeutics Completes $27 Million Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 13 Feb 2012
Valeant Pharmaceuticals to Acquire Eyetech
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 17 Aug 2011
OPKO Invests in Cardiac Device Company
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 11 Feb 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
Biopharmaceuticals Endocrinology Ophthalmology
 HSMN NewsFeed - 8 Feb 2011
Neovasc Inc. Receives CE Mark for Peripatch-Bv Bovine Pericardial Tissue
Devices Regulatory
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 Jun 2010
t2cure's Cellular Therapeutic Receives Orphan Drug Designation from FDA, EMA Recommendation for Buerger's Disease
Biopharmaceuticals Regenerative Medicine FDA Regulatory
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Feb 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Diagnostics Ophthalmology Licensing
 HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Jan 2010
CircuLite(R) Closes on Series C Financing
Devices Cardiology Venture Capital
 HSMN NewsFeed - 15 Dec 2009
Ophthotech Raises $30 Million in Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Oct 2009
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
Biopharmaceuticals Ophthalmology Drug Delivery Licensing
 HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 7 Apr 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Feb 2009
Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Feb 2009
Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
Devices Surgery Personnel Regulatory
 HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jul 2008
Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Jul 2008
Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Jul 2008
Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
Devices Acquisitions
 HSMN NewsFeed - 23 Jun 2008
EyeCyte, Inc. Secures Series A Funding from Pfizer
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 8 May 2008
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Devices Ophthalmology
 HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 27 Mar 2008
Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Jan 2008
Medical Ventures to Acquire Two Vascular Device Developers
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 18 Jan 2008
Novagali Pharma Announces FDA Clearance of IND for US Clinical Trial of Nova63035 in Patients With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Nov 2007
Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2007
Steven Engle Appointed Chairman of XOMA
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 6 Aug 2007
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2007
Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Jun 2007
CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President of Strategic and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2007
Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 May 2007
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Apr 2007
QLT announces that CHMP will recommend to the European Commission that occult indication be deleted from the Visudyne(R)label in European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Feb 2007
XOMA Announces Planned Retirement of Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2007
Athenagen Announces Name Change to CoMentis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2006
Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2006
Carl Zeiss Meditec Announces Installation of 6000th Stratus OCT
Devices Ophthalmology
 HSMN NewsFeed - 8 Nov 2006
OcuCure Therapeutics: Developing Novel Eye Drop Treatments for Wet and Dry Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 16 Oct 2006
Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Biopharmacetuicals Ophthalmology
 HSMN NewsFeed - 4 Oct 2006
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Sep 2006
Athenagen Raises $50 Million in Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 26 Sep 2006
Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy
 HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Sep 2006
XOMA's NEUPREX(R) Granted Orphan Status in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Aug 2006
Cytogen Launches SOLTAMOX(TM), First Oral Liquid Formulation of Hormonal Therapy for Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2006
XOMA Unveils Strategy, Provides Update on NEUPREX(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2006
XOMA Suspends HepeX-B(TM) Work Following Cubist Decision
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2006
OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2006
Cytogen Announces Initiation of Phase III Study Involving QUADRAMET(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2006
Cytogen Announces Publication of Peer-Reviewed Journal Article on QUADRAMET(R)
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 26 Jun 2006
Lumenis Invests in Exclusive, Worldwide License for New Ophthalmic Technology
Devices Ophthalmology Licensing
 HSMN NewsFeed - 21 Jun 2006
Athenagen Advances Angiogenesis Drug to Clinical Testing
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 20 Jun 2006
Cytogen Announces Departure of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2006
Cytogen and Philips Demonstrate PROSTASCINT(R) Image Acquisition and Processing Tools That Improve Efficiency and Reduce Imaging Time
Devices Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2006
Data Presented at SNM Meeting Demonstrate New Potential for PROSTASCINT(R) through Advances in Nuclear Medicine Imaging
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2006
Data Presented at SNM Meeting Demonstrate Novel Therapeutic Combinations and Applications for QUADRAMET(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2006
Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 22 May 2006
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
Diagnostics Urology Oncology
 HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology
 HSMN NewsFeed - 8 May 2006
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2006
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 May 2006
OSI Pharmaceuticals Announces Management Changes to Its Eye Disease Business Team
Biopharmaceuticals Personnel Ophthalmology
 HSMN NewsFeed - 24 Apr 2006
Cytogen and Savient Finalize Exclusive Distribution Agreement for SOLTAMOX(TM)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 17 Apr 2006
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Apr 2006
Athenagen Acquires Osprey Pharmaceutical Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Mar 2006
Hana Biosciences to License Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Mar 2006
Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Feb 2006
Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Feb 2006
Positive Findings from Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients with Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2006
Regeneron's VEGF Trap Demonstrates Positive Preliminary Results in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Feb 2006
OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 2 Feb 2006
European Commission Approves Macugen for Treatment of All Types of Wet Age-Related Macular Degeneration; First Treatment to Target Underlying Disease Process of Wet AMD
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 1 Feb 2006
OSI Pharmaceuticals Announces Fourth Quarter Net Sales for Tarceva(R)'s International Launch
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jan 2006
Preliminary Phase III Data from Head-To-Head Study of Lucentis Shows Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Jan 2006
PR Pharmaceuticals (PRP) Announces Collaboration With OSI Pharmaceuticals to Develop Sustained Release Formulation of Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 119

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 119 additional stories matching:
Neovasc
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.